2,608 Shares in Danaher Co. (NYSE:DHR) Acquired by Net Worth Advisory Group

Net Worth Advisory Group bought a new position in Danaher Co. (NYSE:DHR) during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm bought 2,608 shares of the conglomerate’s stock, valued at approximately $725,000.

Other hedge funds have also recently modified their holdings of the company. Vanguard Group Inc. increased its holdings in Danaher by 7.4% during the 1st quarter. Vanguard Group Inc. now owns 60,107,030 shares of the conglomerate’s stock valued at $15,009,928,000 after purchasing an additional 4,163,657 shares during the period. Swedbank AB bought a new stake in shares of Danaher in the 1st quarter worth approximately $676,545,000. TD Asset Management Inc increased its stake in shares of Danaher by 99.0% during the second quarter. TD Asset Management Inc now owns 1,358,706 shares of the conglomerate’s stock valued at $339,473,000 after buying an additional 675,952 shares during the period. Massachusetts Financial Services Co. MA raised its holdings in shares of Danaher by 22.7% during the second quarter. Massachusetts Financial Services Co. MA now owns 3,047,728 shares of the conglomerate’s stock valued at $761,475,000 after acquiring an additional 563,546 shares in the last quarter. Finally, Castle Hook Partners LP purchased a new stake in Danaher in the first quarter worth $98,913,000. Hedge funds and other institutional investors own 79.05% of the company’s stock.

Insider Transactions at Danaher

In related news, SVP Georgeann Couchara sold 952 shares of Danaher stock in a transaction dated Monday, August 26th. The stock was sold at an average price of $268.37, for a total value of $255,488.24. Following the completion of the sale, the senior vice president now directly owns 4,212 shares in the company, valued at approximately $1,130,374.44. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other news, Director Linda Filler sold 3,928 shares of the firm’s stock in a transaction on Thursday, August 1st. The stock was sold at an average price of $279.50, for a total value of $1,097,876.00. Following the transaction, the director now directly owns 41,149 shares in the company, valued at $11,501,145.50. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, SVP Georgeann Couchara sold 952 shares of the company’s stock in a transaction on Monday, August 26th. The shares were sold at an average price of $268.37, for a total value of $255,488.24. Following the sale, the senior vice president now owns 4,212 shares of the company’s stock, valued at approximately $1,130,374.44. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 39,659 shares of company stock worth $11,042,433 over the last quarter. 11.10% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

A number of brokerages have issued reports on DHR. Royal Bank of Canada reissued an “outperform” rating and set a $300.00 price objective on shares of Danaher in a research report on Friday, September 6th. Robert W. Baird increased their price target on shares of Danaher from $271.00 to $278.00 and gave the stock an “outperform” rating in a research note on Wednesday, July 24th. Leerink Partners lifted their price objective on Danaher from $275.00 to $280.00 and gave the company an “outperform” rating in a research report on Wednesday, July 24th. TD Cowen upped their target price on Danaher from $290.00 to $310.00 and gave the stock a “buy” rating in a report on Wednesday, July 24th. Finally, Evercore ISI raised their target price on Danaher from $275.00 to $278.00 and gave the company an “outperform” rating in a research note on Tuesday, October 1st. Seven research analysts have rated the stock with a hold rating and twelve have given a buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $282.12.

Danaher Stock Performance

Shares of DHR stock opened at $274.33 on Friday. The company has a market capitalization of $203.19 billion, a price-to-earnings ratio of 46.50, a price-to-earnings-growth ratio of 4.49 and a beta of 0.83. The company has a debt-to-equity ratio of 0.33, a quick ratio of 1.04 and a current ratio of 1.43. Danaher Co. has a one year low of $182.09 and a one year high of $281.70. The company’s 50-day moving average is $270.72 and its 200 day moving average is $259.92.

Danaher (NYSE:DHR) last posted its quarterly earnings results on Tuesday, July 23rd. The conglomerate reported $1.72 EPS for the quarter, beating analysts’ consensus estimates of $1.57 by $0.15. Danaher had a net margin of 16.94% and a return on equity of 11.06%. The firm had revenue of $5.74 billion for the quarter, compared to analysts’ expectations of $5.59 billion. During the same quarter in the prior year, the company posted $2.05 earnings per share. The business’s revenue for the quarter was down 2.9% on a year-over-year basis. Sell-side analysts expect that Danaher Co. will post 7.59 EPS for the current fiscal year.

Danaher Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, October 25th. Stockholders of record on Friday, September 27th will be paid a $0.27 dividend. This represents a $1.08 annualized dividend and a dividend yield of 0.39%. The ex-dividend date is Friday, September 27th. Danaher’s dividend payout ratio is currently 18.31%.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.